This study tests a new drug called ziftomenib (KO-539) in people with acute myeloid leukemia (AML) that has come back or not responded to treatment. The drug targets a specific genetic change (MLL rearrangement or NPM1 mutation) found in some patients. The goal is to find the saf…
Phase: PHASE1, PHASE2 • Sponsor: Kura Oncology, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC